Burn surgeon presents health economic model projecting burn center will save up to USD $21 million per year treating patients with the RECELL System compared to conventional treatment Valencia, Calif., USA, and Melbourne, Australia, 13 November 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that key opinion leaders […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-11-13 03:07:452018-11-13 03:07:45Leading Burn Surgeons Present Positive RECELL® System Results at 31st Annual Southern Region Burn CME Conference and Northeast Region Burn Conference
The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the company’s expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% treatment success at the end of therapy Raised gross proceeds of $6.8 million through an […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-11-08 02:53:092018-11-13 02:54:33AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights
Brighton, United Kingdom – 1 November 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, that addresses the global problem of antimicrobial resistance (AMR), today announces it has been jointly awarded a National Biofilms Innovation Centre (NBIC) funded research collaboration with the University of Southampton. The […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-11-01 00:31:402018-11-02 00:33:42Destiny Pharma announces research collaboration with the University of Southampton targeting infections in diabetic foot ulcers and cystic fibrosis
London, UK and Melbourne, Australia, 30 October 2018 – BioScience Managers Limited (BioScience Managers), the international healthcare investment firm today announces the appointment of Dr. Kate Rowley as Investment Director, based in London. Reflecting BioScience Managers’ international focus Dr. Rowley’s role will be to review and evaluate healthcare investment opportunities and manage investment deals from […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-10-30 22:57:412018-10-31 22:58:33BioScience Managers appoints Dr. Kate Rowley as UK-based Investment Director
Cambridge, UK., 30th October 2018: Arecor Ltd (“the Company”), the UK-based leading formulation technology company, focussed on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides, continues to build a strong patent portfolio protecting the Company’s proprietary technology and product assets. Arecor is pleased to announce the successful outcome of the opposition proceedings […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-10-29 00:24:352018-11-02 00:31:12ARECOR SUCCESSFULLY DEFENDS A KEY EUROPEAN PATENT IN OPPOSITION PROCEEDINGS ON THE SUBJECT OF MITIGATION OF AGGREGATION OF THERAPEUTIC PROTEINS DURING STORAGE
Clinical study is being conducted in Brisbane, Australia in collaboration with the Queensland University of Technology and Lady Cilento Children’s Hospital Valencia, Calif., USA, and Melbourne, Australia, 25 October 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that the commencement of a randomized, controlled clinical study of the […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-10-25 03:09:282018-10-26 03:30:06AVITA Medical Announces Commencement of Randomized Controlled Clinical Study of RECELL® System in Treatment of Children with Burn Injuries
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the Company”) Directorate Change […]
Destiny Pharma plc (“Destiny Pharma” or the “Company”) Destiny Pharma’s lead asset, XF-73, well positioned to address the global threat of anti-microbial resistance highlighted in new UK government report Brighton, United Kingdom – 24 October 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs, which address […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-10-24 03:03:262018-10-26 03:04:34UK government highlights global threat of AMR
Destiny Pharma plc (“Destiny Pharma” or the “Company”) A series of videos and explainer documents launched, focusing on cutting-edge R&D taking place in UK biotech companies, including Destiny Pharma Destiny Pharma has been chosen to exemplify the UK’s leading status in antimicrobial resistance research Brighton, United Kingdom – 19 October 2018 – Destiny Pharma (AIM: DEST), […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-10-19 03:01:572018-10-26 03:03:02BIA celebrates UK bioscience in creating innovative new drugs and treatment for patients
Valencia, Calif., USA, and Melbourne, Australia, 18 October 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has received the first commercial sales orders from U.S. burn centers for the RECELL® Autologous Cell Harvesting Device (RECELL® System) and has commenced commercial shipment of the product. The U.S. […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-10-17 03:21:072018-10-19 03:28:29AVITA Medical Announces First U.S. Sales of RECELL® System and Commencement of Commercial Shipping Multiple U.S. burn centers incorporating RECELL System into their practices in advance of national U.S. market launch
Leading Burn Surgeons Present Positive RECELL® System Results at 31st Annual Southern Region Burn CME Conference and Northeast Region Burn Conference
/in Avita MedicalBurn surgeon presents health economic model projecting burn center will save up to USD $21 million per year treating patients with the RECELL System compared to conventional treatment Valencia, Calif., USA, and Melbourne, Australia, 13 November 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that key opinion leaders […]
AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights
/in AmpliPhi BiosciencesThe company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the company’s expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% treatment success at the end of therapy Raised gross proceeds of $6.8 million through an […]
Destiny Pharma announces research collaboration with the University of Southampton targeting infections in diabetic foot ulcers and cystic fibrosis
/in Destiny PharmaBrighton, United Kingdom – 1 November 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, that addresses the global problem of antimicrobial resistance (AMR), today announces it has been jointly awarded a National Biofilms Innovation Centre (NBIC) funded research collaboration with the University of Southampton. The […]
BioScience Managers appoints Dr. Kate Rowley as UK-based Investment Director
/in BioSciences ManagersLondon, UK and Melbourne, Australia, 30 October 2018 – BioScience Managers Limited (BioScience Managers), the international healthcare investment firm today announces the appointment of Dr. Kate Rowley as Investment Director, based in London. Reflecting BioScience Managers’ international focus Dr. Rowley’s role will be to review and evaluate healthcare investment opportunities and manage investment deals from […]
ARECOR SUCCESSFULLY DEFENDS A KEY EUROPEAN PATENT IN OPPOSITION PROCEEDINGS ON THE SUBJECT OF MITIGATION OF AGGREGATION OF THERAPEUTIC PROTEINS DURING STORAGE
/in ArecorCambridge, UK., 30th October 2018: Arecor Ltd (“the Company”), the UK-based leading formulation technology company, focussed on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides, continues to build a strong patent portfolio protecting the Company’s proprietary technology and product assets. Arecor is pleased to announce the successful outcome of the opposition proceedings […]
AVITA Medical Announces Commencement of Randomized Controlled Clinical Study of RECELL® System in Treatment of Children with Burn Injuries
/in Avita MedicalClinical study is being conducted in Brisbane, Australia in collaboration with the Queensland University of Technology and Lady Cilento Children’s Hospital Valencia, Calif., USA, and Melbourne, Australia, 25 October 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that the commencement of a randomized, controlled clinical study of the […]
Directorate Change
/in Destiny PharmaTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the Company”) Directorate Change […]
UK government highlights global threat of AMR
/in Destiny PharmaDestiny Pharma plc (“Destiny Pharma” or the “Company”) Destiny Pharma’s lead asset, XF-73, well positioned to address the global threat of anti-microbial resistance highlighted in new UK government report Brighton, United Kingdom – 24 October 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs, which address […]
BIA celebrates UK bioscience in creating innovative new drugs and treatment for patients
/in Destiny PharmaDestiny Pharma plc (“Destiny Pharma” or the “Company”) A series of videos and explainer documents launched, focusing on cutting-edge R&D taking place in UK biotech companies, including Destiny Pharma Destiny Pharma has been chosen to exemplify the UK’s leading status in antimicrobial resistance research Brighton, United Kingdom – 19 October 2018 – Destiny Pharma (AIM: DEST), […]
AVITA Medical Announces First U.S. Sales of RECELL® System and Commencement of Commercial Shipping Multiple U.S. burn centers incorporating RECELL System into their practices in advance of national U.S. market launch
/in Avita MedicalValencia, Calif., USA, and Melbourne, Australia, 18 October 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has received the first commercial sales orders from U.S. burn centers for the RECELL® Autologous Cell Harvesting Device (RECELL® System) and has commenced commercial shipment of the product. The U.S. […]